Evidence map›Paper›PMID 32367274›Full record

ArticleArchives of toxicology2020

Evaluation of toxicity of aerosols from flavored e-liquids in Sprague-Dawley rats in a 90-day OECD inhalation study, complemented by transcriptomics analysis.

Jenny Ho, Davide Sciuscio, Ulrike Kogel, Bjoern Titz, Patrice Leroy, Gregory Vuillaume, Marja Talikka, Elyette Martin, Pavel Pospisil, Stefan Lebrun and 11 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Archives of toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. The Toxicological Effects of e-Cigarette Use in the Upper Airway: A Scoping Review.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 2 countries.

Jenny HoPMI S&I, Philip Morris International Research Laboratories Pte. Ltd., Science Park II, Singapore, Singapore.
Davide SciuscioPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Ulrike KogelPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Bjoern TitzPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Patrice LeroyPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Gregory VuillaumePMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Marja TalikkaPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Elyette MartinPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Pavel PospisilPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Stefan LebrunPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Wenhao XiaPMI S&I, Philip Morris International Research Laboratories Pte. Ltd., Science Park II, Singapore, Singapore.
Tom LeePMI S&I, Philip Morris International Research Laboratories Pte. Ltd., Science Park II, Singapore, Singapore.
Yun Xuan ChngPMI S&I, Philip Morris International Research Laboratories Pte. Ltd., Science Park II, Singapore, Singapore.
Blaine W PhillipsPMI S&I, Philip Morris International Research Laboratories Pte. Ltd., Science Park II, Singapore, Singapore.
Emilija VeljkovicPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Emmanuel GuedjPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Yang XiangPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Nikolai V IvanovPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Manuel C PeitschPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Julia HoengPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland.
Patrick VanscheeuwijckPMI S&I, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000, Neuchâtel, Switzerland. Patrick.Vanscheeuwijck@pmi.com.ORCID http://orcid.org/0000-0002-8232-1734
Philip Morris International (Switzerland) · CHSingapore Science Park · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of flavoring substances is an important element in the development of reduced-risk products for adult smokers to increase product acceptance and encourage switching from cigarettes. In a first step towards characterizing the sub-chronic inhalation toxicity of neat flavoring substances, a study was conducted using a mixture of the substances in a base solution of e-liquid, where the standard toxicological endpoints of the nebulized aerosols were supplemented with transcriptomics analysis. The flavor mixture was produced by grouping 178 flavors into 26 distinct chemical groups based on structural similarities and potential metabolic and biological effects. Flavoring substances predicted to show the highest toxicological effect from each group were selected as the flavor group representatives (FGR). Following Organization for Economic Cooperation and Development Testing Guideline 413, rats were exposed to three concentrations of the FGR mixture in an e-liquid composed of nicotine (23 µg/L), propylene glycol (1520 µg/L), and vegetable glycerin (1890 µg/L), while non-flavored and no-nicotine mixtures were included as references to identify potential additive or synergistic effects between nicotine and the flavoring substances. The results indicated that the inhalation of an e-liquid containing the mixture of FGRs caused very minimal local and systemic toxic effects. In particular, there were no remarkable clinical (in-life) observations in flavored e-liquid-exposed rats. The biological effects related to exposure to the mixture of neat FGRs were limited and mainly nicotine-mediated, including changes in hematological and blood chemistry parameters and organ weight. These results indicate no significant additive biological changes following inhalation exposure to the nebulized FGR mixture above the nicotine effects measured in this sub-chronic inhalation study. In a subsequent study, e-liquids with FGR mixtures will be aerosolized by thermal treatment and assessed for toxicity.

Indexed as

Electronic Nicotine Delivery SystemsGene Expression ProfilingAnimalsBiomarkersConsumer Product SafetyE-Cigarette VaporFemaleFlavoring AgentsInhalation ExposureLiverMaleRats, Sprague-DawleyRespiratory SystemRisk AssessmentTime FactorsToxicity TestsBiomarkersE-Cigarette VaporFlavoring AgentsE-liquidFlavorInhalation toxicologyOECDSystem toxicology

Identifiers

PMID32367274
PMCPMC7303093
OpenAlexW3023141960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.